How I treat relapsed and/or refractory multiple myeloma

por Lee, Hans C., Cerchione, Claudio
Publicado 2020

The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma

por Becnel, Melody R., Lee, Hans C.
Publicado 2020

The role of bone‐modifying agents in myeloma bone disease

por Lu, Huifang, Pundole, Xerxes, Lee, Hans C.
Publicado 2021

Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes

por Purushothaman, Anurag, Bandari, Shyam K., Chandrashekar, Darshan S., Jones, Richard J., Lee, Hans C., Weber, Donna M., Orlowski, Robert Z.
Publicado 2017

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma

por Tu, Yong-sheng, He, Jin, Liu, Huan, Lee, Hans C., Wang, Hua, Ishizawa, Jo, Allen, Joshua E., Andreeff, Michael, Orlowski, Robert Z., Davis, Richard E., Yang, Jing
Publicado 2017

A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma

por Lee, Hans C., Feng, Lei, Oriabure, Onyeka, Graham, Vivian, Chen, Wendy, Badillo, Maria, Lu, Rebecca, Lee, Hun J., Jain, Preetesh, Manasanch, Elisabet E., Orlowski, Robert Z., Wang, Michael L.
Publicado 2021

PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)

por Holstein, Sarah A., Mian, Hira, Touzeau, Cyrille, Kingsley, Edwin, Vogl, Dan, Zuniga, Richard, Suryanarayan, Kaveri, Wang, Shining, Thesillat-Versmee, Laura, Liu, Yuyin, Chen, Tian, Zhang, Yefei, Parot, Xavier, Lee, Hans C.
Publicado 2023

MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up

por Cohen, Adam D, Lee, Hans C, Trudel, Suzanne, Abdallah, Al-Ola, Callander, Natalie, Libby, Edward, Karlin, Lionel, Lonial, Sagar, Womersley, Lynsey, Baron, January, Lewis, Eric, Nungesser, Katlyn, Gupta, Ira, Opalinska, Joanna
Publicado 2020

Evaluation of contemporary echocardiographic and histomorphology parameters in predicting mortality in patients with endomyocardial biopsy-proven cardiac AL amyloidosis

por Koutroumpakis, Efstratios, Niku, Adam, Black, Christopher K., Ali, Abdelrahman, Sadaf, Humaira, Song, Juhee, Palaskas, Nicolas, Iliescu, Cezar, Durand, Jean-Bernard, Yusuf, Syed Wamique, Lee, Hans C., Buja, L. Maximilian, Deswal, Anita, Banchs, Jose
Publicado 2023

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

por Lee, Hans C., Shah, Jatin J., Feng, Lei, Manasanch, Elisabet E., Lu, Rebecca, Morphey, Ashley, Crumpton, Brandon, Patel, Krina K., Wang, Michael L., Alexanian, Raymond, Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z.
Publicado 2019

Cardiac Magnetic Resonance Predicting Outcomes Among Patients at Risk for Cardiac AL Amyloidosis

por Agha, Ali M., Palaskas, Nicolas, Patel, Amit R., DeCara, Jeanne, Parwani, Purvi, Iliescu, Cezar, Durand, Jean B., Kim, Peter, Hassan, Saamir, Gladish, Gregory, Lee, Hans C., Kaufman, Gregory P., Lopez-Mattei, Juan C.
Publicado 2021

Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up

por Manasanch, Elisabet E., Kunacheewa, Chutima, Claussen, Catherine M., Lee, Hans C., Thomas, Sheeba K., Gunther, Jill, Pinnix, Chelsea C., Dabaja, Bouthaina S., Amini, Behrang, Alexanian, Raymond, Orlowski, Robert Z., Dong, Wenli, Feng, Lei, Weber, Donna M.
Publicado 2021

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma

por Patel, Krina K., Shah, Jatin J., Feng, Lei, Lee, Hans C., Manasanch, Elisabet M., Olsem, Jasper, Morphey, Ashley, Huo, Xiao Jiao, Thomas, Sheeba K., Bashir, Qaiser, Qazilbash, Muzaffar H., Weber, Donna M., Orlowski, Robert Z.
Publicado 2022

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNEC...

por Abonour, Rafat, Rifkin, Robert, Ailawadhi, Sikander, Lee, Hans C., Gasparetto, Christina, Wagner, Lynne, Durie, Brian, Hardin, James, Terebelo, Howard, Narang, Mohit, Toomey, Kathleen, Tang, Yuexin, Dhanasiri, Sujith, Anand, Jasmeet, Yu, Edward, Marshall, Thomas, Liu, Liang, Jagannath, Sundar
Publicado 2023

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

por Terpos, Evangelos, Mikhael, Joseph, Hajek, Roman, Chari, Ajai, Zweegman, Sonja, Lee, Hans C., Mateos, María-Victoria, Larocca, Alessandra, Ramasamy, Karthik, Kaiser, Martin, Cook, Gordon, Weisel, Katja C., Costello, Caitlin L., Elliott, Jennifer, Palumbo, Antonio, Usmani, Saad Z.
Publicado 2021

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

por Richardson, Paul G., Lee, Hans C., Abdallah, Al-Ola, Cohen, Adam D., Kapoor, Prashant, Voorhees, Peter M., Hoos, Axel, Wang, Karrie, Baron, January, Piontek, Trisha, Byrne, Julie, Richmond, Scott, Jewell, Roxanne C., Opalinska, Joanna, Gupta, Ira, Lonial, Sagar
Publicado 2020

PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE

por Hultcrantz, Malin, Kleinman, David, Vij, Ravi, Escalante, Fernando, Delforge, Michel, Kotowsky, Nirali, Bitetti, Jacopo, Boytsov, Natalie, Camadoo-O’byrne, Leena, Happ, Lindsey Powers, Rohman, Mujib, Germain, Guillaume, Duh, Mei Sheng, Laliberté, François, Mahendran, Malena, Urosevic, Ana, Lee, Hans C.
Publicado 2023

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Conn...

por Abonour, Rafat, Rifkin, Robert M., Gasparetto, Cristina, Toomey, Kathleen, Durie, Brian G. M., Hardin, James W., Terebelo, Howard R., Jagannath, Sundar, Narang, Mohit, Ailawadhi, Sikander, Omel, James L., Lee, Hans C., Srinivasan, Shankar, Kitali, Amani, Agarwal, Amit, Wagner, Lynne
Publicado 2020

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect(®) MM Registry

por Lee, Hans C., Ailawadhi, Sikander, Gasparetto, Cristina J., Jagannath, Sundar, Rifkin, Robert M., Durie, Brian G. M., Narang, Mohit, Terebelo, Howard R., Toomey, Kathleen, Hardin, James W., Wagner, Lynne, Omel, James L., Dhalla, Mazaher, Liu, Liang, Joshi, Prashant, Abonour, Rafat
Publicado 2021

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis

por Ailawadhi, Sikander, Jagannath, Sundar, Lee, Hans C., Narang, Mohit, Rifkin, Robert M., Terebelo, Howard R., Durie, Brian G. M., Toomey, Kathleen, Hardin, James W., Gasparetto, Cristina J., Wagner, Lynne, Omel, James L., He, Mia, Yue, Lihua, Flick, Elizabeth Dawn, Agarwal, Amit, Abonour, Rafat
Publicado 2020